NASDAQ · EIKN
Eikon Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EIKN: Nov 12, 2026
Eikon Therapeutics, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.74.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.74 | $-1.70 | $-1.79 | 5 |
| Dec 2026 | $-1.88 | $-1.76 | $-2.00 | 4 |
| Mar 2027 | $-1.85 | $-1.76 | $-1.95 | 3 |
| Jun 2027 | $-1.90 | $-1.83 | $-2.00 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · MarketBeat · BNK Invest- Fintel · Oct 16, 8:04 AM EDTHC Wainwright & Co. Initiates Coverage of Eikon Therapeutics with Buy RatingFintel reports that on October 16, 2026, HC Wainwright & Co. initiated coverage of Eikon Therapeutics (NASDAQGS:EIKN) with a Buy recommendation. Prior to this rating action, Eikon Therapeutics closed at $7.54 on October 15, 2026. Looking at the stock's recent performance, the
- RTTNews · Oct 15, 2:16 PM EDTEikon Submits IND For EIK1006 In Prostate Cancer; Stock Up Over 8%(RTTNews) – Eikon Therapeutics Inc. (EIKN), a late clinical-stage biopharmaceutical company, on Thursday reported the submission of an investigational new drug (IND) application for EIK1006 in treating prostate cancer. Prostate cancer is a malignancy of the prostate gland in ma
- RTTNews · Sep 3, 11:13 AM EDTEikon Therapeutics Appoints Ching-Pin Chang As Executive VP & Chief Scientific Officer(RTTNews) – Eikon Therapeutics, Inc. (EIKN), a late-stage clinical biopharmaceutical company, on Thursday announced the appointment of Dr. Ching-Pin Chang as Executive Vice President and Chief Scientific Officer.
- MarketBeat · Aug 22, 7:01 AM EDTEikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004Eikon Therapeutics (NASDAQ:EIKN) outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen Mansfield. President, Chief Executive Officer and Board Chair Roger Perlmutter and MD An
- RTTNews · Aug 11, 9:33 AM EDTEikon Therapeutics Selects 0.60 Mg/m² Dose For Phase 2/3 EIK1001 Melanoma Trial(RTTNews) – Eikon Therapeutics, Inc. (EIKN), a late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs, announced the selection of a 0.60 mg/m² dose of EIK1001 for the ongoing TeLuRide-006 adaptive Phase 2/3 trial i
- RTTNews · Jul 27, 12:27 PM EDTEikon Doses First Patient In Phase 2/3 TeLuRide For EIK1001 For NSCLC; Stock Up(RTTNews) – Eikon Therapeutics Inc. (EIKN), a late-stage clinical biopharmaceutical company, on Monday reported dosing the first patient in the Phase 2/3 TeLuRide-008 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for treating Stage 4 non-small cell l
- RTTNews · Jul 14, 2:03 AM EDTEupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down(RTTNews) – Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company, announced several leadership changes within the company to support its upcoming planned phase of clinical and commercial growth.
- RTTNews · May 12, 9:50 AM EDTEikon Reports Q1 Loss Of $83 Mln; To Present New Non-Small Cell Lung Cancer Data At The ASCO(RTTNews) – Eikon Therapeutics Inc. (EIKN), a late-stage biopharmaceutical company, on Monday released its first quarter financial results, and provided clinical updates.
- BNK Invest · Feb 9, 10:59 AM ESTMonday 2/9 Insider Buying Report: LW, EIKNBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Eikon Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.